Adenocarcinoma of Esophagogastric Junction Clinical Trials

4 recruitingLast updated: May 5, 2026

There are 9 actively recruiting adenocarcinoma of esophagogastric junction clinical trials across 3 countries. Studies span Not Applicable, Phase 2. Top locations include Ningbo, Zhejiang, China, Taizhou, Zhejiang, China, Lishui, Zhejiang, China. Updated daily from ClinicalTrials.gov.


Adenocarcinoma of Esophagogastric Junction Trials at a Glance

9 actively recruiting trials for adenocarcinoma of esophagogastric junction are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Not Applicable with 4 trials, with the heaviest enrollment activity in Ningbo, Taizhou, and Lishui. Lead sponsors running adenocarcinoma of esophagogastric junction studies include Yu jiren, Huashan Hospital, and Fudan University.

Browse adenocarcinoma of esophagogastric junction trials by phase

Treatments under study

About Adenocarcinoma of Esophagogastric Junction Clinical Trials

Looking for clinical trials for Adenocarcinoma of Esophagogastric Junction? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Adenocarcinoma of Esophagogastric Junction trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Adenocarcinoma of Esophagogastric Junction clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Gastric Cancer (GC)Siewert Type III Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
P. Herzen Moscow Oncology Research Institute400 enrolled1 locationNCT07441785
Recruiting
Not Applicable

A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique

Gastric CancerAdenocarcinoma of Esophagogastric Junction
Huashan Hospital30 enrolled1 locationNCT06300879
Recruiting
Phase 2

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Siewert Type II Adenocarcinoma of Esophagogastric JunctionAdenocarcinoma EsophagusLocally Advanced Adenocarcinoma+1 more
Sakti Chakrabarti25 enrolled1 locationNCT06044311
Recruiting
Not Applicable

Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction

Siewert Type II Adenocarcinoma of Esophagogastric Junction
Xijing Hospital of Digestive Diseases212 enrolled1 locationNCT05356520
Recruiting
Not Applicable

Right Versus Left Thoracic Surgical Approaches for Siewert II Gastroesophageal Junction Adenocarcinoma

Siewert Type II Adenocarcinoma of Esophagogastric Junction
Cancer Institute and Hospital, Chinese Academy of Medical Sciences236 enrolled1 locationNCT06644352
Recruiting
Phase 2

Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

HER2-positive Gastric CancerAdenocarcinoma of the StomachAdenocarcinoma of Esophagogastric Junction
Yu jiren30 enrolled8 locationsNCT05715931
Recruiting
Phase 2

Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)

Adenocarcinoma of the StomachAdenocarcinoma of Esophagogastric JunctionProficient Mismatch Repair
Yu jiren314 enrolled5 locationsNCT05872685
Recruiting
Not Applicable

A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer

Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University58 enrolled1 locationNCT06158919
Recruiting
Phase 2

Perioperative Chemotherapy Plus Toripalimab for dMMR Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma

Mismatch Repair DeficiencyAdenocarcinoma of the StomachAdenocarcinoma of Esophagogastric Junction
Yu jiren90 enrolled8 locationsNCT05729646